Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Medical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diagnosis of osteoporosis and assessment of fracture risk.Lancet. 2002; 359: 1929-1936
- Bone density and fracture risk in men.J Bone Miner Res. 1998; 13: 1915-1923
- Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status.Bone. 2016; 87: 19-26
- Osteoporosis: diagnosis, prevention, therapy.Springer Science & Business Media, 2009
- Effects of Age and Estrogen Status on Serum Parathyroid Hormone Levels and Biochemical Markers of Bone Turnover in Women: A Population-Based Study.J Clin Endocrinol Metab. 1997; 82: 1522-1527
- Clinician’s Guide to Prevention and Treatment of Osteoporosis.Osteoporos Int. 2014; 25: 2359-2381
- 2019 Official Positions Adult.pdf | Powered by Box.(Available at:) (Accessed March 11, 2021)
- Assessment of fracture risk.Osteoporos Int. 2005; 16: 581-589
- The Official Positions of the International Society for Clinical Densitometry: vertebral fracture assessment.J Clin Densitom. 2013; 16: 482-488
- Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.Clin Chem. 2017; 63: 464-474
- Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.J Bone Miner Res. 1999; 14: 792-801
- Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting.Bone. 2002; 31: 57-61
- The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know.J Clin Endocrinol Metab. 2011; 96: 53-58
- Reducing fracture risk with calcium and vitamin D.Clin Endocrinol. 2010; 73: 277-285
- Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis.JAMA Netw Open. 2019; 2: e1917789
- Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women.J Clin Pharmacol. 2000; 40: 1237-1244
- Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos).J Clin Endocrinol Metab. 2013; 98: 3010-3018
- Calcium Intake and Cardiovascular Disease Risk: An Updated Systematic Review and Meta-analysis.Ann Intern Med. 2016; 165: 856-866
- Calcium Supplementation and Coronary Artery Disease: A Methodological Confound?.J Am Coll Nutr. 2020; 39: 383-387
- Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective.J Bone Miner Res. 2009; 24: 693-701
- Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults.Am J Med. 2004; 116: 634-639
- Serum 25-hydroxyvitamin D and risk of major osteoporotic fractures in older U.S. adults.J Bone Miner Res. 2013; 28: 997-1006
- Serum 25-hydroxyvitamin D concentrations and risk for hip fractures.Ann Intern Med. 2008; 149: 242-250
- Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah.J Bone Miner Res. 2004; 19: 537-545
- Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study.J Bone Miner Res. 2000; 15: 2504-2512
- Changes in bone turnover in young women consuming different levels of dietary protein.J Clin Endocrinol Metab. 1999; 84: 1052-1055
- Exercise for preventing and treating osteoporosis in postmenopausal women.Cochrane Database Syst Rev. 2011; : CD000333https://doi.org/10.1002/14651858.CD000333.pub2
- Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention.J Am Geriatr Soc. 2001; 49: 664-672
- The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials.BMJ. 2013; 347: f6234
- Interventions for preventing falls in older people living in the community.Cochrane Database Syst Rev. 2012; https://doi.org/10.1002/14651858.CD007146.pub3
- Fracture Prevention with Zoledronate in Older Women with Osteopenia.N Engl J Med. 2018; 379: 2407-2416
- Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med. 2007; 357: 1799-1809
- Bisphosphonates: mechanisms of action.J Clin Invest. 1996; 97: 2692-2696
- Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.J Bone Miner Res. 1995; 10: 1478-1487
- Bisphosphonates: Mechanism of Action and Role in Clinical Practice.Mayo Clin Proc. 2008; 83: 1032-1045
- Bisphosphonates: Mode of Action and Pharmacology.Pediatrics. 2007; 119: S150-S162
- Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.JAMA. 1998; 280: 2077-2082
- Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.J Bone Miner Res. 2004; 19: 1241-1249
- Effect of Risedronate on the Risk of Hip Fracture in Elderly Women.N Engl J Med. 2001; 344: 333-340
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.Lancet. 1996; 348: 1535-1541
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis.N Engl J Med. 2007; 356: 1809-1822
- Characterization of and risk factors for the acute-phase response after zoledronic acid.J Clin Endocrinol Metab. 2010; 95: 4380-4387
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research.J Bone Miner Res. 2007; 22: 1479-1491
- Severely suppressed bone turnover: a potential complication of alendronate therapy.J Clin Endocrinol Metab. 2005; 90: 1294-1301
- Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.J Bone Joint Surg Br. 2007; 89: 349-353
- Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.N Engl J Med. 2020; 383: 743-753
- Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.J Bone Miner Res. 2016; 31: 16-35
- Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?.N Engl J Med. 2012; 366: 2051-2053
- Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.JAMA. 2006; 296: 2927-2938
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.JAMA. 1999; 282: 637-645
- Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.J Clin Endocrinol Metab. 2019; 104: 1623-1630
- Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.Ann Intern Med. 2014; 161: 711-723
- A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.Arch Intern Med. 2004; 164: 871-879
- Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.J Clin Endocrinol Metab. 2014; 99: E189-E198
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis.N Engl J Med. 2009; 361: 756-765
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.Lancet Diabetes Endocrinol. 2017; 5: 513-523
- Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.Bone. 2017; 105: 11-17
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?.Osteoporos Int. 2012; 23: 327-337
- Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis.J Clin Endocrinol Metab. 2020; 105: 1641-1658
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study.Am J Med. 2000; 109: 267-276
- Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.Br Med J. 1992; 305: 556-561
- Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.Acta Orthop Scand Suppl. 1997; 275: 112-114
- Does salmon calcitonin cause cancer? A review and meta-analysis.Osteoporos Int. 2016; 27: 13-19
- Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.J Bone Miner Res. 2018; 33: 783-794
- Clinical Practice. Postmenopausal Osteoporosis.N Engl J Med. 2016; 374: 254-262
- The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.Osteoporos Int. 2018; 29: 2335-2343
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.JAMA. 2016; 316: 722-733
- Novel actions of sclerostin on bone.J Mol Endocrinol. 2019; 62: R167-R185
- One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.J Bone Miner Res. 2019; 34: 419-428
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.N Engl J Med. 2017; 377: 1417-1427
- Romosozumab in postmenopausal women with low bone mineral density.N Engl J Med. 2014; 370: 412-420
- Improving drug adherence in osteoporosis: an update on more recent studies.Ther Adv Musculoskelet Dis. 2018; 10: 141-149
- Treatment failure in osteoporosis.Osteoporos Int. 2012; 23: 2769-2774
Article info
Publication history
Published online: September 07, 2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
